In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...
In this video interview, Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, explains why scaling pragmatic and decentralized trial approaches, not just piloting them once, ...
Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...
In today's ACT Brief, we examine a major trial retraction and regulatory action against a rare disease drug, regulatory scenarios for selective safety data collection, and FDA's domestic manufacturing ...
In today's ACT Brief, we examine what the FDA's real-time oversight initiative demands of sponsors, why clinical data ...
NEJM editors cited post–database lock readjudication after trial unblinding, undisclosed to two academic authors, as inconsistent with proper research conduct and sufficient to retract the publication ...
In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...
FDA proof-of-concept trials with AstraZeneca and Amgen validate continuous data transmission and signal detection, setting ...
In this video interview following the 2026 DIA Global Annual Meeting, Jonathan Andrus, co-CEO of CRIO, explains why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results